LIVN News and Press, LivaNova PLC From 05/28/20

PERSIST-AVR study results presented at American Association for Thoracic Surgery Annual Meeting LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, presented the first data from the Perceval ® Sutureless Implant Versus Standard-Aortic Valve ...

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the publication of a new study in the International Journal of Bipolar Disorders 1 that showed adding Vagus Nerve Stimulation Therapy (VNS Therapy ® ) to treatment as usual (TAU) si...

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will present new findings from its Perceval ® Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study at the 100 th Annual Meeting of the American Association of...

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald, Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20 at 10:50 a.m. Eastern Time. The discussion will be available to all interest...

Image source: The Motley Fool. LivaNova PLC   (NASDAQ: LIVN) Q1 2020 Earnings Call Apr 29, 2020 , 8:00 a.m. ET Operator Continue reading

LivaNova PLC (LIVN) Q1 2020 Results Conference Call April 29, 2020 08:00 AM ET Company Participants Matthew Dodds - Senior Vice President of Corporate Development Damien McDonald - Chief Executive Officer Thad Huston - Chief Financial Officer Melissa Farina - Vice President of ...

The following slide deck was published by LivaNova PLC in conjunction with their 2020 Q1 earnings Read more ...

LivaNova PLC (NASDAQ: LIVN ): Q1 Non-GAAP EPS of $0.33 misses by $0.10 ; GAAP EPS of $0.79 beats by $0.80 . More news on: LivaNova PLC, Earnings news and commentary, Healthcare stocks news, Read more ...

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020. For the first quarter of 2020, worldwide sales from continuing operations were $242.4 million, a decrease of 3.4 percent on a reported basis...

Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned CE Mark approval for E...